Meloxicam oral suspension: A treatment alternative to solid meloxicam formulations

Inflammation Research

Volumn 50, Issue SUPPL. 1, 2001, Pages

  Hanft, G ^a   Turck D ^a   Scheuerer, S ^a   Sigmund, R ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Bioavailability; Efficacy; Meloxicam; Oral

Indexed keywords

MELOXICAM;

ADULT; ARTHRITIS; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; MALE; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SUSPENSION;

EID: 0035083902     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00000219     Document Type: Article

References (14)

1. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′ isomer
2. Dose-dependent inhibition of platelet cyclooygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects
3. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers
4. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee
5. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee
6. Meloxicam in osteoarthritis: A 6-month, double-blind comparison with diclofenac sodium
7. Evaluation of the safety, tolerability, and efficacy of meloxicam tablets in patients with osteoarthritis
8. Efficacy and safety of meloxicam in patients with rheumatoid arthritis
9. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial
10. Safety of meloxicam: A global analysis of clinical trials
11. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam; results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis
12. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients
13. Meloxicam oral suspension: A treatment alternative to solid meloxicam formulations. 14th Congress of the European League against Rheumatism, Glasgow, 6-11 June 1999
14. A review of the clinical pharmacokinetics of meloxicam